Sunshine Biopharma Inc.

Sunshine Biopharma Inc. announced the closing of its public offering on May 19, 2026, raising approximately $6 million in gross proceeds. The offering consisted of Common Units and Pre-Funded Units, each including shares or pre-funded warrants and two Series C warrants. Aegis Capital Corp. acted as the exclusive placement agent, receiving a 7% fee and a 2% expense allowance. The company anticipates using the net proceeds for general corporate purposes and working capital, with a potential for an additional $12 million if all Series C warrants are fully exercised.

Sunshine Biopharma Inc. reported a Q1 2026 net loss of $1.24 million, widening from $1.18 million in Q1 2025, with sales decreasing by 9.1% to $8.09 million. The company is engaged in a legal dispute over a $5.3 million earnout with a former subsidiary president. Despite financial challenges, the company is advancing its K1.1 mRNA liver cancer drug, which showed positive initial results in animal testing, and plans to launch 12 new generic drugs in 2026.

Sunshine Biopharma Inc. filed an S-1 registration statement for a public offering of up to $6,000,000 in common units and pre-funded units. Each common unit consists of one share of common stock and two Series C Warrants, while pre-funded units include a pre-funded warrant and two Series C Warrants. The company expects to receive approximately $5.0 million in net proceeds, which will be used for general corporate purposes, including working capital. The offering is on a best efforts basis with no minimum amount required to close, and involves significant dilution for existing shareholders.

Sunshine Biopharma Inc. announced its financial results for the fiscal year ended December 31, 2025, reporting total revenue of $36.3 million. This represents a 4.1% increase compared to the prior year, indicating continued top-line growth for the pharmaceutical company. The company focuses on developing life-saving medicines across oncology, antivirals, and other key therapeutic areas, and this revenue growth suggests progress in its commercialization or development efforts.